ANUHPHR · NSE
Anuh Pharma Limited
₹93.48
-0.21% (-₹0.2)
Prev. close
₹93.68
Volume
95,805
Delivery %
55.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Anuh Pharma Limited
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The company also develops products, such as anticoagulant, antagonist, anti convulsants, anty-ulcerative, anty-ulcerative, anticholinergics, anti-anemic, antidepressant, and mucolytic agents. It also exports its products. Anuh Pharma Limited was incorporated in 1960 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ritesh Bipin Shah MBA
Headquarters
Mumbai
Employees
323
Website
anuhpharma.comExchange
View on NSE ↗Key stats
Market cap
₹936.89 Cr
P/E ratio (TTM)
26.1
Dividend yield
1.60%
EPS (TTM)
₹3.58
Beta (1Y · daily vs NIFTY 50)
0.72
Shares float
2.71 Cr
EPS · quarter ended Jun 2026
₹1.14
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹431.96 Cr | ₹486.65 Cr | ₹527.49 Cr | ₹647.00 Cr | ₹661.51 Cr | ₹771.66 Cr | |
| EBITDA | ₹55.12 Cr | ₹52.04 Cr | ₹57.39 Cr | ₹87.25 Cr | ₹70.36 Cr | ₹66.08 Cr |
| ₹28.44 Cr | ₹30.56 Cr | ₹36.18 Cr | ₹60.06 Cr | ₹47.35 Cr | ₹41.05 Cr | |
| Diluted EPS | ₹2.84 | ₹3.05 | ₹3.61 | ₹5.99 | ₹2.36 | ₹4.1 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹332.64 Cr | ₹347.17 Cr | ₹405.00 Cr | ₹446.00 Cr | ₹507.00 Cr | ₹557.00 Cr | |
| ₹13.68 Cr | ₹4.22 Cr | ₹90.67 L | ₹2.69 Cr | ₹10.89 Cr | ₹5.83 L | |
| Stockholders' equity | ₹190.64 Cr | ₹213.77 Cr | ₹241.00 Cr | ₹291.00 Cr | ₹326.00 Cr | ₹352.00 Cr |
CWIP, Others, Long-term debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-19.00 Cr | ₹29.00 Cr | ₹54.00 Cr | ₹13.00 Cr | ₹37.00 Cr | ₹-3.00 Cr | |
| Investing cash flow | — | — | ₹-43.48 Cr | ₹91.82 L | ₹-19.91 Cr | ₹17.84 Cr |
| ₹-33.00 Cr | ₹-19.00 Cr | ₹-12.00 Cr | ₹-9.00 Cr | ₹-5.00 Cr | ₹-26.00 Cr | |
| Capital expenditure | ₹-6.00 Cr | ₹-2.00 Cr | ₹-2.00 Cr | ₹-5.00 Cr | ₹-20.00 Cr | ₹-8.00 Cr |
| End cash position | — | — | ₹1.93 Cr | ₹7.20 Cr | ₹19.56 Cr | ₹8.06 Cr |
Depreciation & amortization, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Jul 25(5Q) | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|
| Promoter | 69.92% | 71.82% | 71.80% |
| Public | 30.08% | 28.18% | 28.20% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Anuh Pharma Limited | ₹938.90 Cr | ₹93.48 | 26.2 | 2.67 | 11.7% | 0.00 | +16.7% | +6.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Anuh Pharma Share Price: Is It a Good Buy After Q1 FY27 Results?
Anuh Pharma reported strong Q1 FY27 results, with revenue increasing 3.9% year-over-year to Rs 194 crore and profit after tax (PAT) climbing 37.6% to Rs 11 crore. The company's share price is currently near Rs 96, close to its 52-week high. Investors are now evaluating if this growth pace can be sustained.